Who we are > FENS-Kavli Scholars > PATRIK VERSTREKEN (2016)

Patrik Verstreken

Country of origin: Belgium


Patrik Verstreken obtained his degree in bio-engineering from the university of Brussels in 1998. He joined the Graduate school of Biomedical sciences at Baylor College of Medicine and under the mentorship of Hugo Bellen he obtained a PhD in Developmental Biology in 2003.  After post doctoral training and with support of a Marie Curie Excellence grant he became a group leader at VIB and joined the faculty of the university of Leuven (KU Leuven) in 2007. Patrik obtained an ERC starting grant in 2011 and an ERC consolidator grant in 2015.

Patrik Verstreken has made contributions to our understanding of synaptic function in health and neurodegenerative disease.  Using fruit flies and more recently also human neurons derived from embryonic stem cells, Patrik’s work has focused on key proteins, lipids and mitochondria that regulate synaptic activity and how these molecules and organelles are misregulated in Parkinson’s disease.  Patrik’s work has led to the discovery of specific presynaptic and organellar defects in Parkinson’s disease and in strategies as to how these defects can be suppressed.


Department of Human Genetics, KU Leuven, Belgium


Previous affiliation
Howard Hughes Medical Institute, Houston, Texas, USA
Previous affiliation
Baylor College of Medicine, Department of Human Genetics, Houston, Texas, USA
Previous affiliation
University of Brussels, Belgium
Ph.D.: Baylor College of Medicine, Houston, Texas, USA


My overarching goal is to understand how synapses are able to maintain functional over their long lives.  Healthy mitochondria are an integral aspect of normal synaptic activity. We have therefore studied the role of pink1 and parkin, two Parkinson’s disease genes that regulate mitochondria. We found Pink1 to regulate ubiquinone coupling in complexI maintaining energy production and normal neurotransmission. In line, we found that Vitamin-K2 is a strong modifier of pink1 and parkin mutants and we showed thatVitamin-K2 acts as an alternative electron carrier in fly and human mitochondria. With the Klein lab we are now engaging in clinical trials and our preliminary work already indicates positive effects in patients.

Synaptic energy ensures proper vesicle trafficking, a process critical to maintain synaptic release. Consequently we analyzed key mechanisms of exo- and endocytosis. Our main contribution has been in analyzing how protein damage induced by the intense cycling of synaptic vesicles is mitigated at synapses.  Nerve terminals are often far from their cell bodies and the novel regulatory mechanisms that control synaptic protein sorting and degradation we have studied are specific to synapses. We have analyzed the role of synaptic endosomes and pathways that involve synapse specific mechanisms of autophagy in the regulation of protein turn-over.  Proteopathic stress and synaptic dysfunction are often connected to neurodegenerative disease, and we discovered several connections between the synapse-specific protein turn-over pathways and Parkinson’s disease as well as other neurodegenerative conditions. Hence, we defined new, medically-relevant mechanisms of protein homeostasis at synapses.